Related Experiment Video
Updated: Jun 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction
Sara Andrabi1, Mir Reza Bekheirnia, Patricia Robbins-Furman
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Insights
Juvenile polyposis syndrome (JPS) linked to SMAD4 mutations also increases risk for hereditary hemorrhagic telangiectasia (HHT). This study identifies aortic and mitral valve disease in a JPS patient with a SMAD4 mutation, suggesting broader cardiovascular risks.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Gastroenterology
Background:
- Juvenile polyposis syndrome (JPS) is genetically linked to SMAD4 or BMPR1A mutations.
- SMAD4 mutations in JPS patients increase the risk of hereditary hemorrhagic telangiectasia (HHT).
- HHT involves SMAD4 or other genes modulating transforming growth factor-beta (TGFβ) signaling, including FBN1, TGFBR1, and TGFBR2, which are associated with Marfan syndrome and Loeys-Dietz syndrome.
Observation:
- A family history positive for aortopathy, mitral valve dysfunction, and JPS was observed.
- Mutation analysis revealed a SMAD4 mutation responsible for these phenotypes within the family.
- This is the first reported case of aortic and mitral disease presenting with JPS in an individual with a SMAD4 mutation.
Findings:
- SMAD4 mutations are implicated in JPS, HHT, and potentially aortic and mitral valve disease.
- The study highlights a novel association between SMAD4 mutations and cardiovascular abnormalities beyond HHT.
- The findings suggest that SMAD4 mutations may confer a broader risk profile than previously understood.
Implications:
- Individuals with SMAD4 mutations should be monitored for cardiovascular complications, including aortic dilation and mitral valve dysfunction.
- Comprehensive medical history review is crucial before molecular testing, particularly for asymptomatic patients.
- This expands the clinical spectrum associated with SMAD4 mutations, impacting diagnostic and management strategies.
Abstract:
Juvenile polyposis syndrome (JPS) is caused by heterozygous mutations in either SMAD4 or BMPR1A. Individuals with JPS due to mutations in SMAD4 are at greater risk to manifest signs of hereditary hemorrhagic telangiectasia (HHT). HHT is caused by either mutations in SMAD4 or other genes that modulate transforming growth factor-beta (TGFβ) signaling. Additional genes in the TGFβ network include FBN1, TGFBR1, and TGFBR2, mutations of which cause either Marfan syndrome (MFS) or Loeys-Dietz syndrome (LDS), respectively. As SMAD4, FBN1, and TGFBR1/2 map to different regions of the genome, disorders associated with mutations in these genes are not expected to co-segregate in a family. We report an individual whose family history was positive for aortopathy, mitral valve dysfunction, and JPS. Mutation analysis of SMAD4 implicates this gene for these phenotypes in this family. Although SMAD4 is among several genes in the TGFβ network, and although prior single case reports have described large vessel aneurysms in HHT, this is the first description of aortic and mitral disease presenting with JPS. This observation suggests that, in addition to HHT, individuals with SMAD4 mutations may be at risk for aortic dilation and mitral valve dysfunction. We emphasize the importance of comprehensive review of the medical history prior to molecular testing, especially in an asymptomatic patient.
More Related Videos
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
08:18Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Published on: December 31, 2014
Related Concept Videos
Pleiotropy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mitral Valve Prolapse I: Introduction
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Mitral Stenosis I: Introduction
Incomplete Dominance